Glucagon-Like Peptide-1(Glp-1) analogs and their derivatives are an important part of diabetes management. These analogs can help to control the blood glucose level more effectively. The term ‘glucagon-type’ is a synonym for glucagon which is a naturally occurring hormone with multiple physiological functions. The glucagon analogs stimulate the pancreas to secrete the hormone. Glucagon-Like Peptide-1 analogs have similar effects as the natural hormone in humans.
LIMITED TIME OFFER – Hurry Up!!!
Buy Now To Avail Flat 30% Off
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/1252
Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Drivers
High prevalence of diabetes is expected to propel growth of the global glucagon-like peptide-1 (glp-1) analogs market over the forecast period. For instance, according to the National Diabetes and Diabetic Retinopathy Survey report published in October 2019, the prevalence of diabetes in India was 11.8% during 2015-2019 and the prevalence of known diabetes cases was 8.0% and new diabetes cases was 3.8% during the period.
Moreover, approval and launch of new products is expected to propel growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, in October 2017, Novo Nordisk received FDA approval for once-a-week GLP-1 analog semaglutide.
Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Opportunities
Patent expiry is expected to offer lucrative growth opportunities for players in the global glucagon-like peptide-1 (glp-1) analogs market. Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017.
Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Restraints
Discontinuation of brands is expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1252
Discontinuation of clinical development is also expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. For instance, in 2016, Roche decided to halt clinical development of Taspoglutide, a molecule targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs, due to high gastrointestinal side effects and hypersensitivity reactions.
High cost of products is expected to hinder growth of the global glucagon-like peptide-1 (glp-1) analogs market. GLP-1 analogs are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medications (US$ 5-9 for 30-day therapy).
Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Competitive Landscape
Major players operating in the global glucagon-like peptide-1 analogs market include, AstraZeneca plc, Eli Lilly and Company, F., Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novo Nordisk, and Sanofi.
Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market: Segmentation
On the basis of drug:
- Exenatide
- Liraglutide
- Lixisenatide
- Dulaglutide
- Semaglutide
- Albiglutide
On the basis of distribution channel:
- Retail Pharmacy
- Hospital pharmacy
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1252
Reasons to Purchase This Report
• Current and future of Glucagon-Like Peptide-1 (Glp-1) Analogs Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Glucagon-Like Peptide-1 (Glp-1) Analogs Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Glucagon-Like Peptide-1 (Glp-1) Analogs Industry Impact
Chapter 2 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Glucagon-Like Peptide-1 (Glp-1) Analogs (Volume and Value) by Type
2.3 Global Glucagon-Like Peptide-1 (Glp-1) Analogs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 6 East Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 7 Europe Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 8 South Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 9 Southeast Asia Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 10 Middle East Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 11 Africa Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 12 Oceania Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 13 South America Glucagon-Like Peptide-1 (Glp-1) Analogs Market Analysis
Chapter 14 Company Profiles and Key Figures in Glucagon-Like Peptide-1 (Glp-1) Analogs Business
Chapter 15 Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837